Stock AnalizIovance Biotherapeutics, Inc. IOVA
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Iovance Biotherapeutics, Inc. (IOVA) is a healthcare company listed in the US with a market value of about $3.6B. In the twelve months to September 30, 2026 it had revenue of $379M and net income of -$221M, a net margin of -58.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -58%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $379M | $264M | $164M | $1M | — | — | — | — | $0 | $0 | $0 |
| Net income | -$221M | -$391M | -$372M | -$444M | -$396M | -$342M | -$260M | -$198M | -$124M | -$92M | -$53M |
| Free cash flow | -$216M | -$336M | -$364M | -$384M | -$313M | -$266M | -$252M | -$166M | -$102M | -$80M | -$34M |
| EPS (diluted) | $-0.50 | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 | $-1.59 | $-1.27 | $-1.41 | $-1.85 |
| Net margin | -58.2% | -148.4% | -226.8% | -37345.4% | — | — | — | — | — | — | — |
| ROIC | — | -53.6% | -51.0% | -69.2% | -68.2% | -49.4% | -29.2% | -52.6% | -21.7% | -50.4% | -25.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $14.50, 87% above the current price; targets range from $8.00 to $20.00; the consensus rating is “Buy”; expected EPS is $-0.38 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Iovance Biotherapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Iovance Biotherapeutics pay a dividend?
Not currently.
Is Iovance Biotherapeutics a good stock to buy?
We do not give buy or sell advice. Iovance Biotherapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.